BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 76.97 |
| Open | 76.17 |
| Bid | 77.48 x 100 |
| Ask | 81.86 x 100 |
| Day's range | 76.14 - 78.03 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,626,477 |
| Market cap | 14.727B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 73.17 |
| EPS (TTM) | 1.06 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 109.31 |
PR NewswireBioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
GuruFocus.comInsider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
© 2024 Yahoo. All rights reserved.